(89)Zr-immunoPET in oncology: state of the art (89)Zr-radiochemistry.
Fiche publication
Date publication
août 2017
Journal
Bioconjugate chemistry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DENAT Franck, Dr GONCALVES Victor
Tous les auteurs :
Heskamp S, Raavé R, Boerman OC, Rijpkema M, Goncalves V, Denat F
Lien Pubmed
Résumé
ImmunoPET with 89Zr-labeled antibodies has shown great potential in cancer imaging. It can provide important information about the pharmacokinetics and tumor targeting properties of monoclonal antibodies and may help in anticipating on toxicity. Furthermore, it allows accurate dose-planning for individualized radioimmunotherapy and may aid in patient selection and early response monitoring for targeted therapies. The most commonly used chelator for 89Zr is desferrioxamine (DFO). Preclinical studies have shown that DFO is a not an ideal chelator, since the 89Zr-DFO complex is partly unstable in vivo, which results in release of 89Zr from the chelator, and subsequent accumulation of 89Zr in bone. This bone accumulation interferes with accurate interpretation and quantification of bone uptake on PET images. Therefore, there is a need for novel chelators that allow more stable complexation of 89Zr. In this review we will describe the most recent developments in 89Zr-radiochemistry, including novel chelators and site-specific conjugation methods.
Mots clés
Animals, Chelating Agents, chemistry, Deferoxamine, chemistry, Drug Delivery Systems, methods, Drug Discovery, methods, Humans, Immunoconjugates, chemistry, Neoplasms, diagnosis, Positron-Emission Tomography, methods, Radiochemistry, methods, Radioisotopes, chemistry, Zirconium, chemistry
Référence
Bioconjug. Chem.. 2017 Aug;: